TY - JOUR
T1 - Neuroimaging of early life epilepsy
AU - Coryell, Jason
AU - Gaillard, William D.
AU - Shellhaas, Renée A.
AU - Grinspan, Zachary M.
AU - Wirrell, Elaine C.
AU - Knupp, Kelly G.
AU - Wusthoff, Courtney J.
AU - Keator, Cynthia
AU - Sullivan, Joseph E.
AU - Loddenkemper, Tobias
AU - Patel, Anup
AU - Chu, Catherine J.
AU - Massey, Shavonne
AU - Novotny, Edward J.
AU - Saneto, Russel P.
AU - Berg, Anne T.
N1 - Publisher Copyright:
Copyright © 2018 by the American Academy of Pediatrics.
PY - 2018/9
Y1 - 2018/9
N2 - OBJECTIVES: We assessed the adherence to neuroimagingguidelines and the diagnostically relevant yield of neuroimaging in newly presenting early life epilepsy (ELE). METHODS: There were 775 children with a new diagnosis of epilepsy (<3 years old at onset) who were recruited through the ELE study at 17 US pediatric epilepsy centers (2012-2015) and managed prospectively for 1 year. The data were analyzed to assess the proportion of children who underwent neuroimaging, the type of neuroimaging, and abnormalities. RESULTS: Of 725 children (93.5%) with neuroimaging, 714 had an MRI (87% with seizure protocols) and 11 had computed tomography or ultrasound only. Etiologically relevant abnormalities were present in 290 individuals (40%) and included: An acquired injury in 97 (13.4%), malformations of cortical development in 56 (7.7%), and other diffuse disorders of brain development in 51 (7.0%). Neuroimaging was abnormal in 160 of 262 (61%) children with abnormal development at diagnosis versus 113 of 463 (24%) children with typical development. Neuroimaging abnormalities were most common in association with focal seizure semiology (40%), spasms (47%), or unclear semiology (42%). In children withoutspasms or focal semiology with typical development, 29 of 185 (16%) had imaging abnormalities. Pathogenic genetic variants were identified in 53 of 121 (44%) children with abnormal neuroimaging in whom genetic testing was performed. CONCLUSIONS: Structural abnormalities occur commonly in ELE, and adherence to neuroimaging guidelines is high at US pediatric epilepsy centers. These data support the universal adoption of imaging guidelines because the yield is substantially high, even in the lowest risk group.
AB - OBJECTIVES: We assessed the adherence to neuroimagingguidelines and the diagnostically relevant yield of neuroimaging in newly presenting early life epilepsy (ELE). METHODS: There were 775 children with a new diagnosis of epilepsy (<3 years old at onset) who were recruited through the ELE study at 17 US pediatric epilepsy centers (2012-2015) and managed prospectively for 1 year. The data were analyzed to assess the proportion of children who underwent neuroimaging, the type of neuroimaging, and abnormalities. RESULTS: Of 725 children (93.5%) with neuroimaging, 714 had an MRI (87% with seizure protocols) and 11 had computed tomography or ultrasound only. Etiologically relevant abnormalities were present in 290 individuals (40%) and included: An acquired injury in 97 (13.4%), malformations of cortical development in 56 (7.7%), and other diffuse disorders of brain development in 51 (7.0%). Neuroimaging was abnormal in 160 of 262 (61%) children with abnormal development at diagnosis versus 113 of 463 (24%) children with typical development. Neuroimaging abnormalities were most common in association with focal seizure semiology (40%), spasms (47%), or unclear semiology (42%). In children withoutspasms or focal semiology with typical development, 29 of 185 (16%) had imaging abnormalities. Pathogenic genetic variants were identified in 53 of 121 (44%) children with abnormal neuroimaging in whom genetic testing was performed. CONCLUSIONS: Structural abnormalities occur commonly in ELE, and adherence to neuroimaging guidelines is high at US pediatric epilepsy centers. These data support the universal adoption of imaging guidelines because the yield is substantially high, even in the lowest risk group.
UR - http://www.scopus.com/inward/record.url?scp=85052726444&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85052726444&partnerID=8YFLogxK
U2 - 10.1542/peds.2018-0672
DO - 10.1542/peds.2018-0672
M3 - Article
C2 - 30089657
AN - SCOPUS:85052726444
SN - 0031-4005
VL - 142
JO - Pediatrics
JF - Pediatrics
IS - 3
M1 - e20180672
ER -